AMY-101, as a highly selective and potent C3 inhibitor, was first successfully used in Italy for the treatment with a COVID-19 patient with severe pneumonia and systemic hyper-inflammation [35–37]. This evidence concerns the gene C3 and susceptibility to pneumonia measurement.